Answers are grounded in this paper and cite their sources.
Cohort study investigates ABCC gene SNVs affecting treatment response in pediatric CNS tumor patients, indicating potential predictive value.
The variability in outcomes among individuals is caused by multiple factors, including genetic variations in drug transporter genes known as ABCs. This study investigates the clinical effect of single-nucleotide variants (SNVs) in the ABCC1/MRP1, ABCC2/MRP2, and ABCC4/MRP4 genes on the clinical response and relapse of pediatric patients with central nervous system tumors. In a cohort-based association study involving 111 cancer patients, genotyping of ABCC1/MRP1, ABCC2/MRP2, and ABCC4/MRP4 was conducted using real-time PCR with TaqMan probes. Treatment response was evaluated using the Response Assessment in Neuro-Oncology (RANO) criteria. Univariate and multivariate analyses were conducted using the Cox proportional hazards (adjusted) model. Multivariate analysis adjusted for sex and age showed a significant association between ABCC1 r.5540out G>C; rs12921623 in the gene and non-response to treatment in the codominant model [HR] 2.095, 95% CI 1.202–3.650, p = 0.009, and in the dominant model [HR] 2.025, 95% CI 1.199–3.421, p = 0.008, and an increased risk of relapse in the codominant model [HR] 9.09, 95% CI 1.04–78.85, p = 0.04, and in the dominant model [HR] 3.912, 95% CI 1.139–13.436, p = 0.03. Furthermore, a significant association was found between ABCC2 c. 3972 C>T; rs3740066 and relapse in the recessive model [HR] 3.5, 95% CI 1.02–12.17, p = 0.04. Our findings indicate that ABCC1 r.5540 G>C SNV and ABCC2 c. 3972 C>T SNV are significant predictors of non-response and relapse in this group of pediatric patients with central nervous system tumors.
No takes yet. Share an insight, caveat, or question.
Torres-Espíndola et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: